Cargando…

Acute optic neuritis: Unmet clinical needs and model for new therapies

Idiopathic demyelinating optic neuritis (ON) most commonly presents as acute unilateral vision loss and eye pain and is frequently associated with multiple sclerosis. Although emphasis is often placed on the good recovery of high-contrast visual acuity, persistent deficits are frequently observed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Galetta, Steven L., Villoslada, Pablo, Levin, Netta, Shindler, Kenneth, Ishikawa, Hiroshi, Parr, Edward, Cadavid, Diego, Balcer, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516397/
https://www.ncbi.nlm.nih.gov/pubmed/26236761
http://dx.doi.org/10.1212/NXI.0000000000000135
_version_ 1782383060187086848
author Galetta, Steven L.
Villoslada, Pablo
Levin, Netta
Shindler, Kenneth
Ishikawa, Hiroshi
Parr, Edward
Cadavid, Diego
Balcer, Laura J.
author_facet Galetta, Steven L.
Villoslada, Pablo
Levin, Netta
Shindler, Kenneth
Ishikawa, Hiroshi
Parr, Edward
Cadavid, Diego
Balcer, Laura J.
author_sort Galetta, Steven L.
collection PubMed
description Idiopathic demyelinating optic neuritis (ON) most commonly presents as acute unilateral vision loss and eye pain and is frequently associated with multiple sclerosis. Although emphasis is often placed on the good recovery of high-contrast visual acuity, persistent deficits are frequently observed in other aspects of vision, including contrast sensitivity, visual field testing, color vision, motion perception, and vision-related quality of life. Persistent and profound structural and functional changes are often revealed by imaging and electrophysiologic techniques, including optical coherence tomography, visual-evoked potentials, and nonconventional MRI. These abnormalities can impair patients' abilities to perform daily activities (e.g., driving, working) so they have important implications for patients' quality of life. In this article, we review the sequelae from ON, including clinical, structural, and functional changes and their interrelationships. The unmet needs in each of these areas are considered and the progress made toward meeting those needs is examined. Finally, we provide an overview of past and present investigational approaches for disease modification in ON.
format Online
Article
Text
id pubmed-4516397
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-45163972015-07-31 Acute optic neuritis: Unmet clinical needs and model for new therapies Galetta, Steven L. Villoslada, Pablo Levin, Netta Shindler, Kenneth Ishikawa, Hiroshi Parr, Edward Cadavid, Diego Balcer, Laura J. Neurol Neuroimmunol Neuroinflamm Views & Reviews Idiopathic demyelinating optic neuritis (ON) most commonly presents as acute unilateral vision loss and eye pain and is frequently associated with multiple sclerosis. Although emphasis is often placed on the good recovery of high-contrast visual acuity, persistent deficits are frequently observed in other aspects of vision, including contrast sensitivity, visual field testing, color vision, motion perception, and vision-related quality of life. Persistent and profound structural and functional changes are often revealed by imaging and electrophysiologic techniques, including optical coherence tomography, visual-evoked potentials, and nonconventional MRI. These abnormalities can impair patients' abilities to perform daily activities (e.g., driving, working) so they have important implications for patients' quality of life. In this article, we review the sequelae from ON, including clinical, structural, and functional changes and their interrelationships. The unmet needs in each of these areas are considered and the progress made toward meeting those needs is examined. Finally, we provide an overview of past and present investigational approaches for disease modification in ON. Lippincott Williams & Wilkins 2015-07-23 /pmc/articles/PMC4516397/ /pubmed/26236761 http://dx.doi.org/10.1212/NXI.0000000000000135 Text en © 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Views & Reviews
Galetta, Steven L.
Villoslada, Pablo
Levin, Netta
Shindler, Kenneth
Ishikawa, Hiroshi
Parr, Edward
Cadavid, Diego
Balcer, Laura J.
Acute optic neuritis: Unmet clinical needs and model for new therapies
title Acute optic neuritis: Unmet clinical needs and model for new therapies
title_full Acute optic neuritis: Unmet clinical needs and model for new therapies
title_fullStr Acute optic neuritis: Unmet clinical needs and model for new therapies
title_full_unstemmed Acute optic neuritis: Unmet clinical needs and model for new therapies
title_short Acute optic neuritis: Unmet clinical needs and model for new therapies
title_sort acute optic neuritis: unmet clinical needs and model for new therapies
topic Views & Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516397/
https://www.ncbi.nlm.nih.gov/pubmed/26236761
http://dx.doi.org/10.1212/NXI.0000000000000135
work_keys_str_mv AT galettastevenl acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT villosladapablo acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT levinnetta acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT shindlerkenneth acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT ishikawahiroshi acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT parredward acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT cadaviddiego acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies
AT balcerlauraj acuteopticneuritisunmetclinicalneedsandmodelfornewtherapies